<DOC>
	<DOCNO>NCT01547806</DOCNO>
	<brief_summary>Background : - One beneficial treatment plasma cell myeloma high-dose chemotherapy follow stem cell transplant . Researchers want collect stem cell blood later transplant . Objectives : - To collect stem cell transplant part treatment plasma cell myeloma . Eligibility : - Individuals least 18 year age chemotherapy stem cell transplant plasma cell myeloma . Design : - Participants screen physical exam medical history . Blood urine sample collect . - Participants filgrastim injection 5 day collection . This move stem cell bone marrow blood . - Participants apheresis collect stem cell . - Participants need additional apheresis procedure collect stem cell filgrastim dose plerixafor improve collection yield .</brief_summary>
	<brief_title>Collection Transplant Stem Cells Plasma Cell Myeloma</brief_title>
	<detailed_description>Background : High-dose chemotherapy follow autologous hematopoietic cell transplant ( AHCT ) remain critical part Plasma Cell Myeloma ( PCM ) treatment subject eligible procedure . The timing procedure however , become controversial recently . This protocol allow collection Hematopoietic Progenitor Cells Apheresis ( HPC , Apheresis ) potential candidate various PCM protocols Clinical Center . The mobilizing agent plerixafor ( Mozobil , Genzyme ) recently approve FDA mobilization PCM . However , best cost effective strategy use remain defined . Objectives : Evaluate overall validity HPC mobilization strategy ( G-CSF alone combination plerixafor ) use formula calculate likelihood collect great equal 5 time 10 ( 6 ) CD34 plus cells/kg single mobilization cycle . Collect mobilize Hematopoietic Progenitor Cells Apheresis ( HPC , Apheresis ) prior AHCT PCM Eligibility : Subjects possible indication AHCT treatment newly diagnose PCM . Subjects recurrent persistent evaluable disease undergone AHCT treatment PCM . Design : Subjects undergo mobilization collection HPC , Apheresis subsequent use various clinical protocol . Mobilization provide 5-daily administration filgrastim accord standard procedure . The need additional mobilizing agent ( plerixafor ) give day 4 mobilization evaluate real time patient , base peripheral blood CD34 count morning day 4 filgrastim administration . Study accrual 3-year period : 70 subject</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>INCLUSION CRITERIA : Multiple Myeloma Criteria : Subjects indication AHCT treatment PCM determine PI LAI . Subjects follow induction treatment PCM Subjects recurrent persistent evaluable disease undergone AHCT treatment PCM . Other Eligibility Criteria : Age great equal to18 year less equal 75 year . In subject 65 75 year age , physiologic age comorbidity thoroughly evaluate enrol . Karnofsky performance status 70 % great ( ECOG 0 1 ) Ejection fraction ( EF ) MUGA 2D echocardiogram within institution normal limit . In case low EF , subject may remain eligible stress echocardiogram perform EF 35 % increase EF stress estimate 10 % . Hgb great equal 8g/dl ( transfusion acceptable ) No history abnormal bleeding tendency . Patients must able give informed consent EXCLUSION CRITERIA : Prior allogeneic stem cell transplantation Hypertension adequately control 3 less medication . Clinically significant cardiac pathology : myocardial infarction within 6 month prior enrollment , Class III IV heart failure accord NYHY , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Specifically , history cardiovascular pathology symptom , clearly fit exclusion criterion prompt evaluation Clinical Center Cardiologist eligibility consider casebycase basis . Should cardiologist deem patient finding workup clinically significant pathology , patient meet exclusion criterion . Patients history coronary artery bypass graft angioplasty receive cardiology evaluation consider casebycase basis . Active hepatitis B C infection HIV seropositive , positive confirmatory nucleic acid test Patients know found pregnant . Patients childbearing age unwilling practice contraception . Patients may exclude discretion PI/LAI deem allow participation would represent unacceptable medical psychiatric risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 27, 2016</verification_date>
	<keyword>Autologous Hematopoietic Cell Transplantation</keyword>
	<keyword>Plasma Cell Myeloma</keyword>
	<keyword>Mobilization</keyword>
	<keyword>Apheresis</keyword>
	<keyword>Plerixafor</keyword>
</DOC>